NYRx Notice to Providers: Baclofen Solution

November 19, 2026

Baclofen solution has been added to the NYRx Cost Optimization Program. Drugs added to the NYRx Cost Optimization Program have entered the market with **substantially higher** launch prices than equally efficacious, cost-effective alternatives. They lack additional clinical utility, while others lack clear medical necessity for those specific formulations and dosages. Baclofen solution will require a Manual Review by NYRx for consideration of coverage approval.

There are clinically- and cost-effective options of the same drug available on the NYRx Clinical Criteria and Coverage Guide, such as baclofen tablets. **Preferred drugs will not require prior authorization if the required coverage parameters are found in the member's Medicaid claim history at the time of pharmacy claim submission.**

XI. Musculoskeletal Agents

Skeletal Muscle Relaxants

Preferred Drugs	Non-Preferred Drugs	Coverage Parameters
baclofen tablet chlorzoxazone 500 mg F/Q/D cyclobenzaprine 5 mg, 10 mg tablet F/Q/D dantrolene methocarbamol F/Q/D	Amrix® F/Q/D Atmeksi® F/Q/D, MR baclofen 15 mg tablet MR baclofen solution MR baclofen suspension (gen Fleqsuvy™)	**STEP THERAPY (ST)** • Trial with one analgesic and two skeletal muscle relaxants prior to use of carisoprodol. **FREQUENCY/QUANTITY/DURATION (F/Q/D)** • PA is required for a quantity exceeding a 14-day supply and up to one refill for initial fill of an antispasmodic skeletal muscle relaxant. • Carisoprodol: Maximum four units per day, 28-day supply.
orphenadrine ER F/Q/D tizanidine tablet F/Q/D	carisoprodol F/Q/D, ST chlorzoxazone F/Q/D chlorzoxazone 250 mg F/Q/D, MR cyclobenzaprine 7.5 mg F/Q/D cyclobenzaprine ER capsule (gen Amrix) F/Q/D Dantrium® Fleqsuvy™ Lyvispah™ metaxalone F/Q/D metaxalone 640 mg tablet F/Q/D, MR methocarbamol 1000 mg F/Q/D, MR Ontralfy™ F/Q/D, MR orphenadrine/aspirin/caffeine F/Q/D, MR Ozobax® MR Ozobax® DS MR Soma® F/Q/D, ST tizanidine capsule F/Q/D tizanidine 8 mg capsule F/Q/D, MR Tonmya™ F/Q/D, MR Zanaflex® F/Q/D	

Resources

- NYRx Education & Outreach Website
- NYRx Clinical Criteria and Coverage Guide
- NYRx Preferred Drug Quick List
- NYRx Prior Authorization Submission Guide

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the NYRx Education & Outreach website for more information.